Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 15: Novel Mechanisms to Enhance Chemotherapy Efficacy

Novel therapy for the metastatic prostate cancer forms by using a combination of gefitinib, tamoxifen and etoposide

Murielle Mimeault, Erik Moore, Jean-Pierre Henichart, Patrick Depreux, Ming-Fong Lin and Surinder K. Batra
Murielle Mimeault
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, College of Medicine, Omaha, NE and Institut de Chimie Pharmaceutique Albert Lespagnol, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Moore
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, College of Medicine, Omaha, NE and Institut de Chimie Pharmaceutique Albert Lespagnol, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Henichart
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, College of Medicine, Omaha, NE and Institut de Chimie Pharmaceutique Albert Lespagnol, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Depreux
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, College of Medicine, Omaha, NE and Institut de Chimie Pharmaceutique Albert Lespagnol, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Fong Lin
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, College of Medicine, Omaha, NE and Institut de Chimie Pharmaceutique Albert Lespagnol, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Surinder K. Batra
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, College of Medicine, Omaha, NE and Institut de Chimie Pharmaceutique Albert Lespagnol, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

2130

Current treatments for prostatic cancer (PC) are generally curative for the majority of patients diagnosed with localized and androgen-dependent forms; however, the progression to the androgen-independent and metastatic disease states is often accompanied by the recurrence of PC. Therefore, the development of a novel combination therapy more effective against anti-androgen- and chemotherapy-refractory PC forms is highly desirable for prostate cancer patients. In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib with other chemotherapeutic drugs including estrogen receptor (ER-β) antagonist (tamoxifen), and topoisomerase II inhibitor (etoposide) on metastatic prostate cancer cells. The results from growth tests and flow cytometric analyses revealed that each drugs alone or at lower concentrations in combination with others inhibited the growth of EGF-, EGF plus 17β-estradiol (E2) and serum-stimulated androgen-sensitive LNCaP-C33 and androgen-independent LNCaP-C81, DU145 and PC3 cells. The antiproliferative effect of gefitinib and tamoxifen, alone or in combination, on EGF plus E2-stimulated PC3 was mediated via a blockade of the PC3 cells in the G1 phase of cell cycle while etoposide induced a G2 arrest. Furthermore, the growth inhibitory effect induced by gefitinib and tamoxifen was also accompanied by the down-regulation of telomerase expression and up-regulation of cell cycle inhibitor proteins, p21Cip1 and p27kip1. Importantly, the combined gefitinib, tamoxifen and etoposide also caused a higher rate of apoptotic death of prostate cancer cells compared to single agents. The cytotoxic effect induced by this tri-combination of drugs in PC3 cells appears to be mediated at least, in part, via the mitochondrial pathway through the depolarization of the mitochondrial membrane and release of cytochrome c and reactive oxygen species into cytosol. This was also accompanied by the cellular ceramide accumulation and activation of caspase cascades and DNA fragmentation. These findings indicate that the combined use of inhibitors of EGF-EGFR and ER-β signaling with other chemotherapeutic agents as etoposide which acting by increasing the cellular ceramide levels and caspase activation represents a promising strategy for a more effective treatment of metastatic prostate cancer forms.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel therapy for the metastatic prostate cancer forms by using a combination of gefitinib, tamoxifen and etoposide
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Novel therapy for the metastatic prostate cancer forms by using a combination of gefitinib, tamoxifen and etoposide
Murielle Mimeault, Erik Moore, Jean-Pierre Henichart, Patrick Depreux, Ming-Fong Lin and Surinder K. Batra
Cancer Res April 15 2006 (66) (8 Supplement) 503;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Novel therapy for the metastatic prostate cancer forms by using a combination of gefitinib, tamoxifen and etoposide
Murielle Mimeault, Erik Moore, Jean-Pierre Henichart, Patrick Depreux, Ming-Fong Lin and Surinder K. Batra
Cancer Res April 15 2006 (66) (8 Supplement) 503;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • 2-Methoxyestradiol in combination with 5-Flourouracil reduces CT-26 tumor volume in mice
  • Sinergistic inhibitory effect of metronomic therapy with oral cyclophosphamide combined with a COX-2 inhibitor in a mouse mammary adenocarcinoma
  • Sequential versus concurrent treatment of breast cancer cell-lines using the farnesyl transferase inhibitor, manumycin A, and mebendazole
Show more Experimental and Molecular Therapeutics 15: Novel Mechanisms to Enhance Chemotherapy Efficacy
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement